CTLA4 and melanoma: We then validated the prediction power of this signature using 411 samples compiled from 6 melanoma cohorts (Supplementary Data 7)16,68–72, in which patients were treated with anti-PD-1 therapy alone or in combination with anti-CTLA-4 therapy.